BYETTA Approved for Use with Insulin Glargine in the U.S.

SAN DIEGO and INDIANAPOLIS, Oct. 19, 2011 /PRNewswire/ — Amylin
Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY)
today announced that the U.S. Food and Drug Administration (FDA) has approved a
new use for BYETTA® (exenatide) injection. BYETTA is now approved as an add-on
therapy to insulin glargine, with or without metformin and/or a
thiazolidinedione (TZD), in conjunction with diet and exercise for adults with
type 2 diabetes who are not achieving adequate glycemic control on insulin
glargine alone.

“This expanded use for BYETTA is important for clinical care, in that it
provides a new option for the many patients with type 2 diabetes who are not
achieving treatment goals,” said John Buse, M.D., Ph.D., professor of medicine,
director of the Diabetes Care Center and chief of the Division of Endocrinology
at the University of North Carolina School of Medicine in Chapel Hill. “BYETTA
is well-suited for use with insulin glargine, offering a simple fixed-dose
regimen that can help improve control of blood sugar overall and after meals. In
a clinical trial, patients using BYETTA with insulin glargine achieved better
glycemic control, without weight gain or an increased risk of hypoglycemia,
compared to patients using insulin glargine alone.”

In the study supporting the expanded use, patients receiving insulin glargine,
with or without metformin and/or a TZD, were randomized to receive BYETTA or
placebo in addition to aggressive insulin titration. After 30 weeks of
treatment, A1C decreased by 1.7 percentage points in patients adding BYETTA,
compared with a decrease of 1.0 percentage point in patients treated with
insulin glargine alone (p<0.001). A1C is a measure of average blood sugar over
three months. Nausea, which was the most common adverse event, occurred in 41
percent of patients treated with BYETTA compared with 8 percent of patients
treated with insulin glargine alone.

“Since 2005, when BYETTA was approved as the first-in-class GLP-1 receptor
agonist, we have continued to investigate its usefulness for patients across the
broad spectrum of type 2 diabetes,” said Christian Weyer, M.D., senior vice
president, research and development, Amylin Pharmaceuticals. “With this
approval, BYETTA is now the first and only GLP-1 receptor agonist approved for
use in the U.S. as an adjunct to insulin glargine, with or without certain oral
agents. This complementary approach to glycemic control will further extend the
use of BYETTA across the continuum of type 2 diabetes care.”

The double-blind clinical trial evaluating BYETTA as an add-on therapy to
insulin glargine was published in Annals of Internal Medicine.(i) In the study,
261 patients receiving insulin glargine with or without metformin and/or a TZD
were randomized to receive BYETTA 10 micrograms or placebo. Patients who may
have been at increased risk of hypoglycemia (A1C<=8 percent) reduced their dose
of insulin glargine by 20 percent. Five weeks after randomization, all patients
had insulin doses aggressively titrated to target fasting blood glucose. The
primary endpoint was reduction in A1C; secondary endpoints included change in
body weight along with other parameters of glucose control, cardiovascular
health, hypoglycemia and patient-reported outcomes.

After 30 weeks of treatment, the proportion of participants achieving the target
A1C<=7 percent was 60 percent in the BYETTA group and 35 percent in the insulin
glargine group (p<0.001). For the target A1C<=6.5 percent, the proportions were
40 percent and 12 percent, respectively (p<0.001). Both groups showed lower
fasting plasma glucose concentrations; however, after morning and evening meals,
when BYETTA was administered, postprandial glucose control was significantly
improved in patients treated with BYETTA, compared to placebo. On average,
weight decreased by 4 pounds in patients adding BYETTA, compared with an
increase of 2 pounds in patients treated with insulin glargine alone (p<0.001).
(BYETTA is not a weight-loss product.) The greater improvement in A1C with
BYETTA was not accompanied by an increase in hypoglycemia, compared to insulin
glargine alone.

Thirteen exenatide recipients and one placebo recipient (9 percent vs. 1
percent) discontinued the study because of adverse events (p<0.010); rates of
nausea (41 percent vs. 8 percent), diarrhea (18 percent vs. 8 percent), vomiting
(18 percent vs. 4 percent), headache (14 percent vs. 4 percent) and constipation
(10 percent vs. 2 percent) were higher with exenatide than with placebo.
Hypoglycemia was similar for both groups; major hypoglycemia occurred twice in
one patient receiving insulin glargine alone.

About Diabetes

Diabetes affects nearly 26 million people in the U.S. and an estimated 347
million adults worldwide.(ii,iii) Approximately 90-95 percent of those affected
have type 2 diabetes. In the U.S., diabetes costs more than $174 billion per
year in direct and indirect medical expenses.(iv)

According to the Centers for Disease Control and Prevention’s National Health
and Nutrition Examination Survey, approximately 60 percent of people with
diabetes do not achieve their target blood sugar levels with their current
treatment regimen.(v) In addition, 85 percent of type 2 diabetes patients are
overweight and 55 percent are considered obese.(vi) Data indicate that weight
loss (even a modest amount) supports patients in their efforts to achieve and
sustain glycemic control.(vii,viii)

About BYETTA® (exenatide) injection

BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be
approved by the FDA for the treatment of type 2 diabetes. BYETTA exhibits many
of the same effects as the human incretin hormone GLP-1. GLP-1 improves blood
sugar after food intake through multiple effects that work in concert on the
stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar
(glucose) control in adults with type 2 diabetes mellitus, when used with a diet
and exercise program. It can also be used with metformin, a sulfonylurea, a
thiazolidinedione or Lantus® (insulin glargine), which is a long-acting insulin.

BYETTA is not insulin and should not be taken instead of insulin. BYETTA should
not be taken with short- and/or rapid-acting insulin. BYETTA is not for people
with type 1 diabetes or people with diabetic ketoacidosis. BYETTA has not been
studied in patients with a history of pancreatitis. Other antidiabetic therapies
should be considered for these patients.

BYETTA provides sustained A1C control with potential weight loss (BYETTA is not
a weight-loss product). BYETTA was approved in the U.S. in April 2005 and in
Europe in November 2006 and has been used by more than 1.8 million patients
since its introduction. See important safety information below. Additional
information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on post-marketing data, BYETTA has been associated with acute
pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing
pancreatitis. Patients should be observed for signs and symptoms of pancreatitis
after initiation or dose escalation of BYETTA. The risk of getting low blood
sugar is higher if BYETTA is taken with another medicine that can cause low
blood sugar, such as a sulfonylurea or insulin. The dose of sulfonylurea or
insulin may need to be lowered while BYETTA is used. BYETTA should not be used
in people who have severe kidney problems and should be used with caution in
people who have had a kidney transplant. Patients should talk with their
healthcare provider if they have severe problems with their stomach, such as
delayed emptying of the stomach (gastroparesis) or problems with digesting food.
Antibodies may develop with use of BYETTA. Patients who develop high titers to
exenatide could have worsening or failure to achieve adequate glycemic control.
Consider alternative therapy if this occurs. Severe allergic reactions can
happen with BYETTA. There have been no clinical studies establishing conclusive
evidence of macrovascular risk reduction with BYETTA or any other antidiabetic
drug.

The most common side effects with BYETTA include nausea, vomiting, diarrhea,
feeling jittery, dizziness, headache, acid stomach, constipation and weakness.
Nausea most commonly happens when first starting BYETTA, but may become less
over time.

These are not all the side effects from use of BYETTA. A healthcare provider
should be consulted about any side effect that is bothersome or does not go
away.

For additional important safety information about BYETTA, please see the full
Prescribing Information (www.BYETTA.com/pi) and Medication Guide
(www.BYETTA.com/mg).

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving
lives of patients through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection
and BYETTA® (exenatide) injection. Amylin’s research and development activities
leverage the Company’s expertise in metabolism to develop potential therapies to
treat diabetes and obesity. Amylin is headquartered in San Diego and has a
commercial manufacturing facility in Ohio.

Through a long-standing commitment to diabetes care, Lilly provides patients
with breakthrough treatments that enable them to live longer, healthier and
fuller lives. Since 1923, Lilly has been the industry leader in pioneering
therapies to help healthcare professionals improve the lives of people with
diabetes, and research continues on innovative medicines to address the unmet
needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Lilly provides answers – through
medicines and information – for some of the world’s most urgent medical needs.

This press release contains forward-looking statements about Amylin and Lilly.
Actual results could differ materially from those discussed or implied in this
press release due to a number of risks and uncertainties, including the risk
that BYETTA and the revenues generated from BYETTA may be affected by
competition; unexpected new data; safety and technical issues; clinical trials
not confirming previous results or not being predictive of real-world use;
pre-clinical trials not predicting future results; label expansion requests not
being submitted in a timely manner or receiving regulatory approval; approved
label expansions not producing the results we expect, or manufacturing and
supply issues. The potential for BYETTA may also be affected by government and
commercial reimbursement and pricing decisions, the pace of market acceptance,
or scientific, regulatory and other issues and risks inherent in the
commercialization of pharmaceutical products including those inherent in the
collaboration with and dependence upon Amylin and/or Lilly. These and additional
risks and uncertainties are described more fully in Amylin’s and Lilly’s most
recent SEC filings including their Quarterly Reports on Form 10-Q and Annual
Reports on Form 10-K. Amylin and Lilly undertake no duty to update these
forward-looking statements.

BYETTA® and SYMLIN® are registered trademarks of Amylin Pharmaceuticals, Inc.
All other marks are the marks of their respective owners.

P-LLY

(i) Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in
basal insulin-treated patients with type 2 diabetes: A randomized, controlled
trial. Ann Intern Med. 2011;154:103-112.

(ii) Diabetes Statistics. American Diabetes Association. Available at:
http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed October
18, 2011.

(iii) Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends
in fasting plasma glucose and diabetes prevalence since 1980: systematic
analysis of health examination surveys and epidemiological studies with 370
country-years and 2.7 million participants. Lancet. 2011;DOI:10.1016/S0140-6736
(11)60679-X.

(iv) Direct and Indirect Costs of Diabetes in the United States. American
Diabetes Association. Available at:

http://www.diabetes.org/how-to-help/action/resources/cost-of-diabetes.html.

Accessed October 17, 2011.

(v) Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular
disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-42.

(vi) Bays HE, Chapman RH, Grandy S. The relationship of body mass index to
diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two
national surveys. Int J Clin Pract. 2007;61:737-47.

(vii) Nutrition Recommendations and Interventions for Diabetes: a position
statement of the American Diabetes Association. Diabetes Care. 2008;31 Suppl
1;S61-78.

(viii) Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in
type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr.
2003;22:331-9.

(Logo: http://photos.prnewswire.com/prnh/20101117/LA02582LOGO)

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company